Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-β for supratentorial glioblastoma: Results of RTOG 9710

Conclusion: RhIFN-β given after conventional radiation therapy was well tolerated, with a trend toward survival benefit in patients who remained stable after radiation therapy. These data suggest that rhIFN-β warrants further evaluation in additional studies, possibly in combination with current temozolomide-based regimens.